# PT-141: A Friendly Guide to Bremelanotide and What the Research Found > PT-141 (bremelanotide) is a melanocortin receptor agonist FDA-approved only for low sexual desire in premenopausal women. A warm, plain-English digest of what the trials measured and how it's tolerated. A plain-spoken digest of the brain-level mechanism, the one approved use, the off-label questions, and an honest look at how it's tolerated — every clinical number cited to its study. ## The short version PT-141 is bremelanotide, a small lab-made peptide that switches on melanocortin MC3R/MC4R receptors (brain switches that help set sexual desire, appetite, and skin pigment). It works in the brain, not on blood flow. The FDA approved it in June 2019 for exactly one thing — persistent low sexual desire that causes real distress in premenopausal women, called HSDD. Every other use you may read about, including in men, is off-label and rests on early research only. The honest catch: the benefit is real but modest, and nausea is common. We walk through all of it, gently and cited. ## What PT-141 is, in one breath PT-141 is the original research designation for **bremelanotide**, a synthetic cyclic heptapeptide (a small lab-made ring of seven amino acids) modeled on alpha-MSH — a natural hormone your body already makes. Where alpha-MSH and its relatives touch skin color, appetite, and arousal, bremelanotide was tuned to lean on the arousal side by activating melanocortin receptors in the brain [1]. Its cyclic ring shape makes it sturdier than a plain straight-chain peptide. The single fact worth pinning down first: this is an approved prescription drug, not an experiment looking for a result. The U.S. Food and Drug Administration approved bremelanotide injection in June 2019 (application NDA 210557) [6]. What that approval covers, though, is narrow — and the rest of this site is mostly the careful business of separating what the approval actually says from what the internet says about it. If you want the brain-level story first, start with [how PT-141 works](/how-it-works); if you want the candid tolerability picture, jump to [PT-141 side effects](/side-effects). ## The one use it's approved for Bremelanotide is approved for acquired, generalized **hypoactive sexual desire disorder (HSDD** — persistent, distressing low sexual desire that isn't better explained by something else) in premenopausal women [6]. "Acquired" means the desire used to be there and faded; "generalized" means it's not tied to one partner or one situation. The approval rested on two large, identical Phase 3 trials called RECONNECT, which together enrolled 1,267 premenopausal women with HSDD [3]. Over 24 weeks, a single 1.75 mg dose taken under the skin as needed improved sexual desire and lowered the distress that low desire caused, compared with placebo [3]. Both of those were the trial's main goals, and both were met. We report the size of that benefit honestly on the research page — it is statistically real and clinically modest, and we don't dress it up. Read it in full at [the RECONNECT Phase 3 trials](/research). ## Where the data stop: men, performance, and the off-label gap Here is the boundary, drawn clearly. PT-141 is **not** approved for men, for erectile dysfunction, for postmenopausal women, or to "enhance" sexual performance [6]. There is genuinely interesting early research in men — dose-ranging studies decades ago produced erectile responses, and a combination program with a different drug class is active — but "early and investigational" is exactly what it is, and we never describe it as established [1] [9]. The same honesty applies to two other things people search for. Because the MC4R receptor also sits in appetite circuits, a couple of small early-phase studies in women saw reduced body weight — but only at a dosing frequency far above anything approved, and weight loss is not an approved use [7]. And material sold online as a "PT-141 research chemical" is a laboratory reagent, not the approved finished medicine — a different thing with no oversight of its identity or purity [6]. The full off-label picture lives under [PT-141 for men (off-label and investigational)](/research) and [MC4R, appetite, and body weight](/research). ## The honest tolerability note, up front We put this near the top on purpose. The most common side effect of PT-141 is **nausea**, and in the long-term study it was the leading reason people stopped — roughly 40% of participants felt it [4]. Flushing (about 21%) and headache (about 12%) are next, followed by injection-site reactions and nasal congestion [4]. The label also flags a brief rise in blood pressure paired with a small drop in heart rate, which is why it is not for people with uncontrolled high blood pressure or known heart disease [6]. With repeated, frequent dosing, some focal darkening of skin or gums has been reported, tied to a different melanocortin receptor [6]. None of that is meant to scare you off the topic — it's meant to give you the real picture before anyone else gives you the marketing one. We lay out every documented effect, with its frequency and its source, on the [PT-141 side effects](/side-effects) page, and we keep the unverified community reports clearly separated from the trial data. ## How to read this site Think of this as a friendly reading desk, not a storefront and not a clinic. Each page teaches one piece: [how PT-141 works](/how-it-works) explains the [central melanocortin (MC3R/MC4R) mechanism](/how-it-works) in plain terms; the research page covers what the trials measured and where the human data stop; the dosage page reports the approved label figures and the pharmacology as findings, never as instructions; and the [frequently asked questions about PT-141](/faq) answer the things people most often type into a search bar. Everywhere we make a number claim, you'll find a bracketed link to the [cited references](/references) so you can check it yourself. --- A friendly, plain-English guide to the PT-141 (bremelanotide) research — the one approved use, the modest benefit, and the nausea-led tolerability cost read first and cited to source, with community field reports kept gently to one side and clearly marked unverified; a reading desk, not a shop, and nothing here dosed, sourced, or sold.